Pfizer launches Web site for tracking pipeline compounds

Share this article:
Pfizer today launched a new Web site that allows investors and members of the scientific and medical communities to track the progress of compounds in the firm’s research and development pipeline. The new Web site, at www.pfizer.com/pipeline, features descriptions of the eleven major therapeutic areas and 63 diseases at the center of Pfizer’s R&D efforts. The Web site will be updated twice-a-year, Pfizer said. “We have the largest and most diverse pipeline in our history. One of our most important business priorities is bringing these compounds forward so that they reach the patients who need them and drive our long-term growth,” said John LaMattina, Pfizer’s president of global research and development. “We have set specific and realistic goals for introducing a steady stream of new products in the years ahead -- four internally developed products by 2011 plus two externally acquired products by 2010 -- and we look forward to reporting on our progress.” Today’s launch of the Web site follows Pfizer’s commitment made at its Nov. 30 R&D day, to make pipeline details available before the end of 2006. The Web site launch also comes in the wake of Pfizer’s announcement earlier this month to halt all clinical trials for torcetrapib, once the most highly touted drug in its pipeline, due to safety concerns. The decision has forced the firm to accelerate its cost-cutting measures and acquisition activity and raised questions about the future of the company, analysts said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...